Table 2.

Clinical significance of predictive biomarkers in chronic lymphocytic leukemia

Predictive biomarkers	Clinical significance
Del 17p/ TP53 mutation	Predicts poor response to chemo-immunotherapy
NOTCH1 mutation	Predicts poor response to anti-CD20 therapy
CD49d	Inhibits cell trafficking in the setting of novel BCR target therapy
IGHV mutation status	Gives its potential for long-term remission in the use of BCR in younger, fit patients with M-IGHV
Complex karyotypes	Predict poor response to chemo-immunotherapy when complex karyotypes with major structural abnormalities.
MicroRNAs	MiR-34a: associates with chemotherapy-refractory disease MiR-155: predicts therapy response